Reference is made to the stock exchange announcement published by Observe
Medical ASA (the "Company") on 12 December 2023 regarding the final results of
the rights issue of 137,193,548 new shares in the Company ("Offer Shares"), each
with a nominal value of NOK 0.26, at a subscription price of NOK 0.26 per share
(the "Rights Issue").

The share capital increases pertaining to the issuance of the 137,193,548 Offer
Shares in the Rights Issue have today been registered with the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret).

The Company's registered share capital is NOK 49,578,153.04 divided into
190,685,204 shares, each with a nominal value of NOK 0.26.

For further information, please contact:

Rune Nystad, CEO Observe Medical

Mobile: +47 916 24 683

E-mail: rune.nystad@observemedical.com

Per Arne Nygård, CFO Observe Medical

Mobile: +47 411 04 345

E-mail: perarne.nygard@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.